Apeloa Pharmaceutical Co Ltd operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Apeloa Pharmaceutical Co Ltd with three other
companies in this sector in China:
Shandong Xinhua Pharmaceutical Company Limited
sales of 5.21 billion Chinese Renmimbi [US$738.68 million]
of which 49%
Shenzhen Hepalink Pharmaceutical Group Co Ltd
(4.81 billion Chinese Renmimbi [US$682.90 million]
of which 100%
was Pharmaceutical Manufacturing), and
ChangChun High New Technology Industries
(5.32 billion Chinese Renmimbi [US$754.96 million]
of which 89%
Apeloa Pharmaceutical Co Ltd reported sales of 6.38 billion Chinese Renmimbi (US$904.43 million)
December of 2018.
increase of 14.9%
versus 2017, when the company's sales were 5.55 billion Chinese Renmimbi.
Sales at Apeloa Pharmaceutical Co Ltd have increased during each of the previous five years
(and since 2013, sales have increased a total of 64%).
Sales of Healthcare and Pharmaceutical saw an increase
15.2% in 2018, from
5.53 billion Chinese Renmimbi to 6.36 billion Chinese Renmimbi.
Not all segments of Apeloa Pharmaceutical Co Ltd experienced an increase in sales in 2018:
sales of Other fell 53.3% to 11.69 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).